Navigation Links
Ohio State University Medical Center to Test Efficacy of Hyperbaric Oxygen Medicine on Stroke Victims

ANAHEIM, Calif., May 20 /PRNewswire/ -- With the financial support of Sechrist Industries, Inc., The Center for Minimally Invasive Surgery (CMIS) at the Ohio State University Medical Center has begun testing the efficacy of hyperbaric oxygen medicine on experimental stroke models. CMIS is a multidisciplinary center dedicated to excellence in patient care, clinical training, research and outcomes studies pertaining to the techniques and technology of minimally invasive surgery.

Currently utilized for the treatment of chronic, non-healing wounds, carbon monoxide poisoning, crush injuries as well as other indications, the use of hyperbaric medicine for stroke victims is at the forefront of hyperbaric research. Hyperbaric oxygen therapy is the treatment of the entire body with 100-percent oxygen at greater than normal atmospheric pressures. Hyperbaric medicine greatly increases oxygen concentration in all body tissues, even with reduced or blocked blood flow, stimulates the growth of new blood vessels to locations with reduced circulation (improving blood flow to areas with arterial blockage) and causes a rebound arterial dilation after treatment, resulting in an increased blood vessel diameter greater than when therapy began, thus improving blood flow to compromised organs. The CMIS team is hopeful that these benefits of hyperbaric oxygen treatments will positively affect stroke patients.

"Ohio State University Medical Center is one of the finest health care institutions in the country," stated Jack Rollins, President and CEO of Sechrist Industries, Inc. "As the world leader in hyperbaric oxygen technology, we feel that it is important to join forces with CMIS to support research in the field of hyperbaric medicine."

"We believe that there is a window of opportunity to treat stroke related injury of the brain using hyperbaric oxygen. The challenge lies in accurately defining the perimeters of that window," says Chandan Sen, Director of the Comprehensive Wound Center at the Ohio State University Medical Center.

For additional information, contact Monica Gutierrez ( or visit

ABOUT Sechrist Industries -- Sechrist is the leading manufacturer of monoplace HBO chambers in the USA, and supplies more monoplace chambers than all other manufacturers combined with over 2000 installed around the world.

SOURCE Sechrist Industries, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Data re-analysis shows drug finasteride reduces risk for most prostate cancers
2. Forty-Two Free Clinics Across State Share $1 Million in Grants From Blue Cross Blue Shield of Michigan
3. Pennsylvania Attorney General Corbett Announces a Multi-state, $58 Million Settlement With Merck Over Deceptive Advertising Concerning the Safety of Vioxx
4. Mapping of prostate cancer genes opens the door to new treatments
5. Radiation for Prostate Cancer Raises Risk of Other Cancers
6. MR imaging accurately determines prostate cancer treatment failure
7. ACS Expands State Medicaid Presence with $156 Million Tennessee Contract
8. New data show benefit of finasteride in preventing prostate cancer
9. Prostate Cancer Vaccine Looks Promising in Early Trial
10. AUDIO from Medialink, Oral Health America & Philips Sonicare: National Smile Month - Giving Americans Something to Smile About Survey Reveals State of Americans Oral Health
11. Paramedics, EMTs in Oregon, Washington State Ratify First-Ever Teamsters Contract
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... 26, 2015 , ... The Catalent Applied Drug Delivery Institute ... integrate dose form selection in early phase drug development. The first of these ... bringing together the UK’s emerging life sciences companies, corporate partners, and investors, at ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/26/2015)... Aliso Viejo, CA (PRWEB) , ... November 26, ... ... X users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. ... custom style options. These classically-influenced trailer titles work with any font, giving users ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... 26, 2015 --> ... SyMRI to find optimal contrast weighting of MRI for ... has signed a research agreement with SyntheticMR in order to ... SyMRI, it is possible to generate multiple contrast images from ... patient has left, thus making it possible to both fine ...
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
Breaking Medicine Technology: